EyePoint Appoints Veteran Commercial Leader with 175,000 Options for DURAVYU Phase 3 Launch
EyePoint hired Michael Campbell as Chief Commercial Officer, granting him 175,000 stock options vesting over four years at the Feb. 17 closing price. Campbell brings 30 years of ophthalmology commercial leadership and will lead Phase 3 launch readiness for DURAVYU with topline wet AMD data expected mid-2026.
1. Appointment of Michael Campbell
EyePoint named Michael Campbell as Chief Commercial Officer effective February 18, 2026. He will report directly to President and CEO Jay Duker and serve on the executive leadership team.
2. Role in DURAVYU Commercialization
Campbell will oversee the commercial strategy and launch readiness for DURAVYU, the intravitreal vorolanib insert in Phase 3 development for wet AMD and diabetic macular edema. Topline data for wet AMD are expected mid-2026, with first patient dosing in the pivotal DME trial in the first quarter of 2026.
3. Industry Track Record and Option Award
With over 30 years of leadership in retinal disease, Campbell led launches of Lucentis, Xiidra and Tyrvaya at Genentech, Novartis, Shire and Viatris. EyePoint granted him 175,000 inducement stock options at the Feb. 17 closing price, vesting 25% after one year and monthly thereafter through year four.